Skip to main content
. Author manuscript; available in PMC: 2010 Jun 3.
Published in final edited form as: Nanomedicine (Lond). 2010 Apr;5(3):379–396. doi: 10.2217/nnm.10.7

Figure 1. A pictorial scheme for cell-based nanoformulated drug delivery.

Figure 1

Three possible ways of BMM-mediated therapeutic effects of catalase nanozyme in PD mouse model: Pathway I: BMM loaded with nanozyme cross the BBB and release catalase in the SNpc; Pathway II: nanozyme is released from BMM to the blood stream and bypasses the BBB independently of cell-carriers; Pathway III: BMM-released catalase nanozyme in the liver and spleen suppresses peripheral leukocyte activation that results in significant protection of nigrostratial neurons against MPTP-induced neurodegeneration.